FCS Press Releases

Three Florida Cancer Specialists & Research Institute (FCS) physicians presented clinical research findings at the American Society of Clinical Oncology (ASCO®) 2022 Genitourinary Cancers Symposium held February 17 – 19 in San Francisco, CA.

Medical oncologists Lucio  N. Gordan, MD and Ivor Percent, MD, members of the clinical research team at Florida Cancer Specialists & Research Institute (FCS), are co-authors for a study that examined the safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC) administered primarily in community-based settings.

Lime Connect (Lime) is pleased to announce that Nathan H. Walcker, Chief Executive Officer of Florida Cancer Specialists & Research Institute, has joined the not for profit organization as a member of its global board of directors.

Dr. Phelan identified the chromosome variant now known as Phelan-McDermid Syndrome

FCS announced the newest addition to its senior management team. Joshua Eaves joined FCS as Senior Vice President Corporate Development.

Hodgkin lymphoma, named after Dr. Thomas Hodgkin, is a cancer that affects the lymphatic system which makes up part of the body’s immune system. Specifically, Hodgkin lymphoma occurs when the DNA changes in white blood cells called lymphocytes.

Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologists Ivor Percent, MD, Maen Hussein, MD, and Viralkumar Bhanderi, MD, contribute observations for Phase II study. Another presentation at ASCO GI 2022 includes Phase I observations from FCS physician, Manish R. Patel, MD.

The sports world is mourning the loss of Jim Corsi who passed away after a battle with liver and colon cancer.

Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist Gail Lynn Shaw Wright, MD, FACP, FCCP is co-author of a Phase II study that examined the efficacy of administering Trilaciclib prior to chemotherapy in patients with metastatic triple-negative breast cancer.

Physicians from FCS presented studies on blood cancer research at the American Society of Hematology Annual Meeting and Exposition.

The inaugural Metastatic Breast Cancer Heroes™ winners were announced by CURE Media Group, recognizing individuals making a difference in the lives of those affected by metastatic breast cancer.  Among the three winners is Florida Cancer Specialists & Research Institute, LLC (FCS) oncology nurse Brandi Riber, RN, based in Fort Myers.

Medical oncologist Manish R Patel, MD, a member of the clinical research team at Florida Cancer Specialists & Research Institute , LLC (FCS), first-authored a study examining dose escalation of an oral complete estrogen receptor (ER) antagonist (CERAN)/selective ER degrader (SERD) in cases of advanced and/or metastatic estrogen receptor-positive, HER2-negative breast cancer.

Medical oncologist James Reeves, MD, a member of the clinical research team at Florida Cancer Specialists & Research Institute (FCS), is co-author of a study that examined the use and effectiveness of niraparib, a targeted therapy drug, to reduce the recurrence of HER2-negative, BRCA mutated breast cancer. Entitled, “Correlation Between Presence of Circulating Tumor DNA and Response to Neoadjuvant Niraparib in HER2-Negative, BRCA-Mutated Breast Cancer,” the study will be shared in a poster presentation at the San Antonio Breast Cancer Symposium being held Dec. 7 – 12, 2021.

A television commercial produced by Florida Cancer Specialists & Research Institute has been recognized in the 42nd Annual Telly Awards, which honors excellence in video and television as judged by leaders representing video platforms around the world.

Florida Cancer Specialists & Research Institute, LLC (FCS) today reported key quality and savings metrics as measured within the most recent performance period from The Centers for Medicare & Medicaid Innovation (CMMI) for the Oncology Care Model (OCM).

Florida Cancer Specialists & Research Institute (FCS) is pleased to announce the following promotions and additions to its senior leadership team.